Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDA NASDAQ:CYCN NASDAQ:PRFX NASDAQ:XFOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$2.37+0.4%$2.25$1.63▼$4.66$12.28M0.81275,367 shs80,653 shsCYCNCyclerion Therapeutics$3.63+4.5%$3.11$1.27▼$9.47$11.64M1.551.27 million shs46,599 shsPRFXPainReform$1.37-2.1%$1.80$1.25▼$16.63$2.75M0.561.22 million shs27,078 shsXFORX4 Pharmaceuticals$1.53-2.5%$2.89$1.49▼$26.96$8.86M0.54198,660 shs56,540 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia+2.54%+14.69%+5.68%+22.53%-20.13%CYCNCyclerion Therapeutics+2.31%+7.41%+13.06%+38.67%+4.11%PRFXPainReform+1.45%-2.37%-31.71%-32.69%-28.28%XFORX4 Pharmaceuticals-5.42%-20.10%-55.90%-75.08%-91.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCDABioCardia4.0065 of 5 stars3.85.00.00.03.82.50.6CYCNCyclerion Therapeutics0.5145 of 5 stars0.03.00.00.00.03.30.0PRFXPainReform1.3201 of 5 stars0.04.00.00.02.41.70.6XFORX4 Pharmaceuticals4.785 of 5 stars3.52.00.04.61.93.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 3.50Strong Buy$25.00954.85% UpsideCYCNCyclerion Therapeutics 0.00N/AN/AN/APRFXPainReform 2.00HoldN/AN/AXFORX4 Pharmaceuticals 3.00Buy$72.334,627.67% UpsideCurrent Analyst Ratings BreakdownLatest PRFX, BCDA, XFOR, and CYCN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025XFORX4 PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.50 ➝ $7.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardia$60K204.61N/AN/A$0.18 per share13.17CYCNCyclerion Therapeutics$2M5.82N/AN/A$3.27 per share1.11PRFXPainReformN/AN/AN/AN/A$2.08 per shareN/AXFORX4 Pharmaceuticals$2.56M3.46N/AN/A$3.90 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)CYCNCyclerion Therapeutics-$3.06M-$1.16N/A∞N/AN/A-34.02%-30.68%8/6/2025 (Estimated)PRFXPainReform-$14.59M-$147.33N/A∞N/AN/AN/AN/A8/21/2025 (Estimated)XFORX4 Pharmaceuticals-$37.45M$2.140.71N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)Latest PRFX, BCDA, XFOR, and CYCN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BCDABioCardia-$0.39-$0.59-$0.20-$0.59N/AN/A5/1/2025Q1 2025XFORX4 Pharmaceuticals-$4.13$0.04+$4.17$0.04$7.03 million$28.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/APRFXPainReformN/AN/AN/AN/AN/AXFORX4 PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.360.36CYCNCyclerion TherapeuticsN/A4.214.21PRFXPainReformN/A1.811.81XFORX4 Pharmaceuticals3.303.703.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%CYCNCyclerion Therapeutics75.62%PRFXPainReform37.28%XFORX4 Pharmaceuticals72.03%Insider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%CYCNCyclerion Therapeutics34.30%PRFXPainReform34.40%XFORX4 Pharmaceuticals2.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia405.18 million4.14 millionOptionableCYCNCyclerion Therapeutics303.21 million2.11 millionNo DataPRFXPainReform42.01 million1.32 millionNot OptionableXFORX4 Pharmaceuticals805.79 million5.65 millionOptionablePRFX, BCDA, XFOR, and CYCN HeadlinesRecent News About These CompaniesX4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 0.3% - Should You Sell?July 10 at 2:23 AM | americanbankingnews.comX4 Pharmaceuticals, Inc. (XFOR) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comX4 Pharmaceuticals Inc News (XFOR) - Investing.comJuly 2, 2025 | investing.comXFOR X4 Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comX4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)June 16, 2025 | globenewswire.comX4 Pharmaceuticals Gets Fast Track Regulatory Designation for Neutropenia DrugJune 10, 2025 | marketwatch.comX4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropeniaJune 10, 2025 | msn.comX4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDAJune 10, 2025 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comX4 Pharmaceuticals Reports Positive Phase 2 Trial Results for Mavorixafor in Chronic Neutropenia, Accepted for Presentation at EHA CongressMay 16, 2025 | nasdaq.comX4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA CongressMay 14, 2025 | globenewswire.comX4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ...May 2, 2025 | finance.yahoo.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call TranscriptMay 2, 2025 | insidermonkey.comX4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call TranscriptMay 1, 2025 | seekingalpha.comX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1, 2025 | finance.yahoo.comX4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 1, 2025 | globenewswire.comX4 Pharmaceuticals Q1 2025 Earnings PreviewApril 30, 2025 | msn.comX4 Pharmaceuticals Analyst RatingsApril 30, 2025 | benzinga.comEarnings Preview For X4 PharmaceuticalsApril 30, 2025 | benzinga.comWhy X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025April 30, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRFX, BCDA, XFOR, and CYCN Company DescriptionsBioCardia NASDAQ:BCDA$2.37 +0.01 (+0.42%) As of 09:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Cyclerion Therapeutics NASDAQ:CYCN$3.62 +0.16 (+4.47%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.PainReform NASDAQ:PRFX$1.37 -0.03 (-2.14%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.X4 Pharmaceuticals NASDAQ:XFOR$1.53 -0.04 (-2.55%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
